salvia occidentalis/kansè

Lyen an sove nan clipboard la

Chwazi kalite sòt

14 rezilta yo

Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Traditional Chinese medicine (TCM) and dendritic cells (DCs) activation/maturation One of the important approaches to successful cancer immunotherapy is generation of specific T cell responses by dendritic cells (DCs). DCs are the most potent antigen-presenting cells for naive T cells, because their

A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Anlotinib Hydrochloride is a kind of innovative medicines approved by State Food and Drug Administration（CFDA:2011L00661） which was developed by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Study on the Optimal Strategy for Acute-on-chronic Liver Failure With Integrative Treatment

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Study design This prospective, multi-center, parallel, centrally randomized controlled trial was designed in accordance with the Consolidated Standards of Reporting Trials (CONSORT) and Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines, which is led by the

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Tumor heterogeneity leads to a significant difference in the rate of response to drugs in patients with the same pathological type. According to the information, the current initial effective rate of domestic and foreign chemotherapeutic single drug is no more than 30%, even if treated with repeated

Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.To compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer

A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hepatocellular carcinoma (HCC) is one of the most common malignances seen in different regions of the world. Surgical resection provides the best chance of cure for selected patients. However, we have long been perplexed by high rates of tumor recurrence, which is often the main cause of long-term

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This is a Phase I/IIa, multicenter, open-label, dose-escalation study. The study will be conducted in 6 phases: "2B3-101 single agent dose-escalation phase", "a 2B3-101 with trastuzumab dose-escalation phase", "a Breast cancer brain metastases study-expansion phase","a Recurrent malignant glioma

Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVES: Primary Objectives: •To examine if low-risk, as defined by clinical and radiological parameters, stage IB-IIB cervical cancer patients treated by cisplatin-based CCRT have greater toxicities but similar survival rate as those treated by RT alone. Secondary Objectives: •To conduct a

Development of Active Safety Surveillance System for Traditional Chinese Medicine

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye